CellSight Technologies

CellSight Technologies is a private, pre-revenue biotech focused on a diagnostic imaging platform for the immune system. Its core technology, the VisAcT (18F-AraG) PET tracer, selectively accumulates in activated T cells, providing a non-invasive window into immune activity. The company is actively advancing its platform through multiple investigator-sponsored clinical trials, primarily in non-small cell lung cancer (NSCLC), with the goal of guiding and improving immunotherapy outcomes. Its long-term vision extends to neurodegenerative and cardiac diseases where immune activation plays a key role.

VisAcT (18F-AraG) PET imaging platform: a radiotracer that selectively accumulates in activated T cells due to phosphorylation by mitochondrial deoxyguanosine kinase (dGK), enabling non-invasive, whole-body visualization and quantification of T cell immune responses.

CellSight competes in the emerging immuno-imaging space against other companies developing PET tracers for immune cells (e.g., targeting CD8, CD3). It also faces indirect competition from liquid biopsy companies offering circulating biomarkers for immunotherapy monitoring. Its differentiation lies in VisAcT's specific mechanism targeting activated T cell metabolism.